1. Pink Sheet

EMA Reviewing Cardiovascular & Cancer Risk From Five Janus Kinase Inhibitors

 
• By Neena Brizmohun

The European Medicines Agency has been asked to make a recommendation by 30 September on whether the marketing authorization for the products concerned should be maintained, varied, suspended or revoked.

Wooden blocks with the word Review. Customer review concept. Reviewing, auditing, reviewer. Service rating. Feedback.
A review into the safety of five JAK inhibitors has started • Source: Alamy

The European Medicines Agency is starting to review the safety of five EU-approved Janus kinase (JAK) inhibitors that are used to treat chronic inflammatory disorders, due to concerns over an increased risk of developing a cardiovascular problem and cancer.

The safety review will focus on Xeljanz (tofacitinib) and Cibinqo (abrocitinib), both from Pfizer, and Jyseleca (filgotinib), Olumiant (baricitinib)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Safety

More from Pink Sheet

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

 
• By Francesca Bruce

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 
• By Michael McCaughan

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.